Why the study?
The role of antiarrhythmic drugs, particularly flecainide, in modifying ECG parameters in Brugada syndrome patients remains underexplored.
Does a 300 mg oral dose of flecainide alter QT interval and QT dispersion in patients with or suspected of having Brugada syndrome?
Does a 300 mg oral dose of flecainide alter QT interval and QT dispersion in patients with or suspected of having Brugada syndrome?
Flecainide administration significantly alters QT and QTc intervals in non-Brugada patients but not in Brugada syndrome patients, highlighting its potential diagnostic utility.
Answers are grounded in this paper and cite their sources.
Flecainide QT effects may aid BrS differentiation; hypothesis-generating and should not change practice yet.
Background: Brugada syndrome (BrS) is a genetic cardiac disorder characterized by specific electrocardiogram (ECG) abnormalities and a heightened risk of sudden cardiac death. The role of antiarrhythmic drugs, particularly flecainide, in modifying ECG parameters in BrS patients’ remains underexplored. Objectives: This study aims to evaluate the effects of flecainide on the QT interval and QT dispersion in patients diagnosed with or suspected of having BrS. Methods: A retrospective analysis was conducted involving 20 patients, divided into two groups: Ten diagnosed with BrS and 10 without. Each participant received a 300 mg oral dose of flecainide, followed by continuous ECG monitoring for 24 hours. Key ECG parameters, including the QT interval, QTc interval, and QT dispersion, were analyzed pre-and-post-administration. Results: Post-flecainide administration, a significant increase in the right QT interval was observed in the overall cohort (P = 0.04). Notably, while BrS patients exhibited changes, none were statistically significant. In contrast, non-BrS patients showed significant increases in left QTD, right QT, and right QTc intervals (P = 0.02, P = 0.03, P = 0.02, respectively). Conclusions: Flecainide significantly alters ECG parameters, particularly in non-Brugada patients, emphasizing its diagnostic utility in confirming BrS. These findings highlight the need for refined diagnostic strategies and tailored management approaches for patients at risk of arrhythmogenic events.
No takes yet. Share an insight, caveat, or question.
Eftekhari et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: